Corcept Therapeutics (CORT) in Focus: Stock Rises 5.8% - Tale of the Tape

Corcept Therapeutics Incorporated (NASDAQ: CORT) was a big mover last session, as its shares rose almost 6% on the day. This reverses the downtrend for the company since May 5, as the stock is now down nearly 53%.

In the last 30 days, the company witnessed three negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday's move higher can last.

Corcept Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.

Some better-ranked medical stocks include Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Astellas Pharma, Inc. (ALPMY) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). All three companies sport a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ASTELLAS PHARMA (ALPMY): Get Free Report
 
ARIAD PHARMA (NASDAQ: ARIA): Free Stock Analysis Report
 
BIOCRYST PHARMA (NASDAQ: BCRX): Free Stock Analysis Report
 
CORCEPT THERAPT (NASDAQ: CORT): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research